While preclinical data is promising, its important to recognize that neither peptide is FDA-approved for human therapeutic use, and most evidence is derived from animal or laboratory studies
publicly stated that 14 of 19 previously Category 2 peptides including BPC-157 would return to Category 1 compounding status
CSII use is associated with small improvements in HbA 1c and fewer hypoglycaemic events, suggesting that CSII can be considered in people living with type 2 diabetes treated with multiple daily insulin injections and able to manage the device [71]
Certain beta-blockers, such as metoprolol, propranolol, and atenolol, should not typically be used to treat hypertension in patients with obesity owing to their weight-promoting effects
When meals are smaller or skipped, the bowel doesnt receive the same signals to contract and move waste along leading to sluggish digestion
Semaglutide injection, for subcutaneous use